Intellectual Property


Control of the lentiviral vector vaccination field
due to a broad & solid intellectual property position

The Pasteur Institute has built a broad and strong patent portfolio covering the use of any gene tranfer vector incorporating the DNA flap sequence. Through our R&D activities and breackthrough discoveries, we aim at further expanding our IP leading position in lentiviral vectors for both human & veterinary vaccination applications.

In 2007, THERAVECTYS & The Pasteur Institute have executed a worldwide exclusive IP licensing agreement
covering the use and the production of lentiviral vectors for vaccination applications


Prophylactic & therapeutic human & veterinary vaccination applications
against all pathologies & pathogens, incl. cancer.


Production & commercialization
of GMP clinical material.